Head and Neck Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Head and Neck Cancer is a $3.5B market that appears mature and consolidated, dominated by off-label uses of products developed for other indications.
Key Trends
- Dominated by single products with secondary indication status (75% of spending from XTANDI, a prostate cancer drug)
- Limited pipeline with 356 total trials heavily weighted toward early phases (96 Phase 1, 117 Phase 2)
- Immuno-oncology mechanisms emerging but representing <2% of market share despite clinical interest
Career Verdict
This is a cautious opportunity: the market is stable but shows limited innovation in primary HNC therapies, making it best suited for specialists in repurposing existing oncology assets rather than breakthrough discovery.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | XTANDI (enzalutamide) | Astellas | $2.6B | 75% | Peak | Stable | 10.7yr |
| 2 | TASIGNA (nilotinib) | Novartis | $395M | 11% | Peak | Stable | 6.4yr |
| 3 | ISENTRESS (raltegravir) | Merck & Co. | $131M | 4% | Peak | Declining | 3.3yr |
Drug Class Breakdown
stable but patent cliff 2037
stable
declining with patent cliff 2029
stable
growth potential but currently underpenetrated
Career Outlook
StableHead and Neck Cancer represents a stable but not expanding specialty within oncology, characterized by mature market dynamics and limited novel therapy development. Most commercial opportunity derives from optimizing existing multi-indication products rather than launching HNC-specific breakthroughs. Career growth is best pursued through large oncology franchises (J&J, Roche, AstraZeneca) that can leverage HNC as one indication among many, rather than through HNC-specialized biotech.
Breaking In
Entry-level professionals should join HNC roles at Tier-1 companies as a stepping stone to broader oncology career paths, since HNC alone does not sustain deep specialization—use it to build multi-indication expertise.
For Experienced Professionals
Experienced oncology professionals should evaluate HNC roles based on company trajectory and broader franchise strength rather than HNC-specific growth; patent cliff timing (XTANDI 2037) suggests mid-career moves away from dependent franchises.
In-Demand Skills
Best For
Hiring Landscape
The indication supports 6,110 total jobs across 15 companies, with commercial roles dominating (1,128 jobs, 18% of total). Hiring is concentrated in large-cap oncology players (J&J, AstraZeneca, Sanofi) that treat HNC as a secondary indication within broader oncology portfolios. Compensation is competitive for oncology, with Clinical Operations roles commanding premium salaries ($307K avg).
By Department
Strong hiring in commercial roles but concentrated at large diversified oncology companies; specialists should prioritize J&J and AstraZeneca for stability, but expect limited HNC-specific career progression.
On Market (1)
Approved therapies currently available
Competitive Landscape
68 companies ranked by most advanced pipeline stage
+38 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 5,133 patients across 50 trials
Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)
Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Adaptive Radiation Treatment for Head and Neck Cancer
CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Zalutumumab in Patients With Non-curable Head and Neck Cancer
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
Capsaicin Lozenges in Treating Patients With Mucositis Caused by Radiation Therapy
Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer
Safety and Efficacy of APG-157 in Head and Neck Cancer
ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Hypoxia Analysis in Head and/or Neck Cancer
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
Phase II Study of TAS-106 to Treat Head and Neck Cancer
Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
Zalutumumab in Non-curable Patients With SCCHN
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck
Related Jobs in Oncology
Medical Science Liaison/Senior Medical Science Liaison - Northeast
Medical Science Liaison/Senior Medical Science Liaison - South Central
Manager, Technical Operations and Supply Chain Management
Manager/Sr. Manager, Clinical GCP Quality Assurance
Clinical Oncology Specialist, Head & Neck Oncology
Clinical Oncology Specialist, Head & Neck Oncology
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.